AESTHETICS INDUSTRY VETERAN PAT ALTAVILLA JOINS SUNEVA MEDICAL AS VICE PRESIDENT OF MARKETING

San Diego, Calif. (October 10, 2016)Suneva Medical, Inc., a privately-held aesthetics company, today announced the appointment of Pat Altavilla as vice president of marketing. With more than 30 years of experience in the aesthetics and medical fields, Altavilla will oversee all marketing aspects for the company, further fortifying the brand’s strong leadership position.

“Pat’s experience marketing aesthetics products is unmatched,” said Preston Romm, president and chief executive officer at Suneva Medical. “With our focus on growing and solidifying Suneva Medical’s position as an aesthetics leader, we feel confident that Pat is more than qualified to help us advance our visibility and strengthen our relationships with key stakeholders.”

Early in her career Altavilla served as vice president of international sales and worldwide marketing for Mentor Corporation, a leader in breast aesthetics, where for nearly 20 years she helped the company grow sales tenfold, launch new products, enhance its global market presence and sales training. Following Mentor Corporation, Altavilla worked as vice president of sales, marketing and operations officer at The Plastic Surgery Company. From there, Altavilla co-founded and ran a medical spa, Spa Medicu/Medicus Skin Enhancement, for several years upon returning to a corporate executive position with BioForm Medical, now part of Merz Aesthetics. During her time with BioForm, Altavilla served in numerous positions, most notably, vice president of global marketing where she was instrumental in restructuring marketing, growing sales, creating a practice development program and raising the company’s overall visibility in the marketplace.

Most recently, Altavilla worked for medical technology company ZELTIQ® Aesthetics Inc. where she served in numerous leadership roles including vice president of global physician and practice marketing and vice president, global strategic partnerships and practice development. With ZELTIQ, Altavilla was instrumental in developing the brand’s global marketing organization as well as growing physician loyalty, enhancing practice development, launching innovative products, and increasing the company’s presence.

“Suneva has a remarkable portfolio of truly innovative products with an impressive arsenal of landmark clinical studies,” said Pat Altavilla.” As the brand embarks on the next chapter of growth and innovation, I’m looking forward driving and strengthening all facets of its market presence.”

For more information on Suneva Medical, visit sunevamedical.com/old.

About HealthCare Royalty Partners

HealthCare Royalty Partners (HCRP) is a global healthcare investment firm focused on investing primarily in commercial stage healthcare product assets. HCRP is based in Stamford, Connecticut and manages over $3 billion in capital. Over the past decade, HCRP’s co‐founders have completed more than 60 healthcare financings totaling more than $2.5 billion of capital. For more information, visit www.healthcareroyalty.com.

About Essex Woodlands

With $2.5 billion under management, Essex Woodlands is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services and healthcare information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing and/or management of over 150 healthcare companies, ranging across sectors, stages and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York and London. For more information, please see www.ewhv.com.

About Suneva Medical, Inc.

Suneva Medical is a privately‐held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. The company markets Bellafill® in the U.S., Canada and Hong Kong; ArteFill® in South Korea; Regenica® skin care in the U.S., Canada and Hong Kong; and ReFissa® tretinoin cream in the U.S. ArteFill® was rebranded to Bellafill® in the U.S. to reflect the transformational outcomes this unique product can provide to patients seeking correction of their acne scars and nasolabial folds. For more information, visit sunevamedical.com/old.[/vc_column_text][/vc_column][/vc_row]

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.